FDA requests removal of suicide warning labels from GLP-1 weight-loss medications

FDA's Proposal for Label Changes

On Tuesday, the Food and Drug Administration announced its intention to eliminate suicide warning labels from GLP-1 weight-loss drugs.

Findings from Comprehensive Trials

The FDA conducted an examination of 91 trials, pitting GLP-1 recipients against placebo participants. Researchers discovered that the 60,338 individuals who used the weight-loss medications exhibited no greater likelihood of suicidal thoughts or actions than the 47,572 in the control groups.

Drugs Targeted by the Update

The medications impacted include liraglutide, marketed by Novo Nordisk under Saxenda; semaglutide, also from Novo Nordisk as Wegovy; and tirzepatide, offered by Eli Lilly under Zepbound, according to the FDA.

Alignment with Diabetes Counterparts

The proposed new labeling for these weight-loss treatments will mirror the information on their diabetes-approved counterparts—specifically, Novo Nordisk's Ozempic and Rybelsus, along with Eli Lilly's Mounjaro.

These diabetes drugs have never featured language pertaining to suicidal thoughts or behaviors in their labels.

Statements from Manufacturers

An Eli Lilly representative shared with Pharmaceutical Technology that 'we appreciate the FDA's careful consideration of this important safety issue. Patient safety is Lilly's top priority, and we will continue to work with the FDA on next steps to ensure that appropriate safety information is available to prescribers.'

A Novo Nordisk spokesperson conveyed to Pharmaceutical Technology that 'we are happy to see the FDA's recommendation to remove the warning regarding the risk of suicidal ideation and behaviour ... We prioritise patient safety and will continue to collaborate closely with the FDA and other regulatory authorities.'